NSPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NSPR is not a good buy right now for a beginner with a long-term preference and $50,000-$100,000 to invest. The stock is trading in a weak technical position, there is no supportive proprietary buy signal, no recent news catalyst, and the latest analyst revisions point to lowered price targets after a product recall and withdrawn guidance. Based on the current data, I would avoid buying and would not treat this as a suitable long-term entry today.
The technical setup is bearish. MACD histogram is below zero and still expanding negatively, which indicates downside momentum. The moving averages are stacked bearishly with SMA_200 > SMA_20 > SMA_5, showing the stock is in a downtrend. RSI_6 at 22.987 is deeply oversold, but not yet a clear reversal signal. Price at 0.90 is below the pivot at 1.018 and only slightly above S1 at 0.893, which suggests the stock is testing support rather than breaking out. The nearby support levels are 0.893 and 0.816, while resistance sits at 1.144 and 1.221. The modeled stock trend also points to further weakness over the next day, week, and month.
["Piper Sandler maintained an Overweight rating.", "Piper noted Q1 sales of $3.4M beat consensus estimates of $2.7M.", "The company still has positive Wall Street recognition for its micromesh carotid stent technology.", "The issue was described by analysts as manageable and contained to the delivery system."]
["No news in the recent week, so there is no fresh catalyst supporting the shares.", "A voluntary recall of the CGuard Prime 135 cm delivery system disrupted the U.S. launch.", "The company withdrew its 2026 revenue guidance of $13M-$15M.", "Price targets were cut by both Piper Sandler and Lake Street.", "The stock trend model implies near-term downside over the next day, week, and month.", "No AI Stock Picker signal today.", "No SwingMax signal recently."]
A full latest-quarter financial snapshot was not available due to a data error, but the analyst commentary provides the key quarter context: Q1 sales were $3.4M versus consensus of $2.7M, which is a positive top-line beat. The quarter also reflected strength in both U.S. and non-U.S. business, and it was the second full quarter of the U.S. launch. However, that progress was overshadowed by the temporary discontinuation of U.S. commercial activity tied to the recall, and management withdrew 2026 guidance, which weakens the near-term financial outlook.
Recent analyst sentiment remains cautiously positive but clearly weakened. Piper Sandler lowered its price target to $3 from $4 and kept an Overweight rating, while Lake Street cut its target to $4 from $5 and kept a Buy rating. The Wall Street pros still like the underlying technology and view the recall issue as manageable, but the lowered targets and guidance withdrawal show reduced confidence in the near-term setup. Bottom line: analysts are still constructive on the long-term story, but their price targets and expectations have come down.
